Ph.D. from Tufts University, USA. Previously CEO of CMAB BioPharma, President of SIMCERE PHARMA (listed in HKEX), CEO of Kanghong Biotech (listed in China), and Staff Scientist of Genzyme Corporation (now part of Sanofi). Led CMAB to become the fastest growing CDMO company in China, acquired by WuXi Biologics. At Simcere, managed a global team of more than 1,700 staff and multiple companies. At Kanghong, developed and marketed Conbercept, the first innovative biologics with an INN to reach 1 billion RMB revenue in China and the first approved by the FDA to directly enter phase III in the US. At Genzyme, a key team member for the development of the first US FDA-approved tissue engineering product.